澳洲

Subscribe to 澳洲

作者：金杜律师事务所 King & Wood Mallesons

King & Wood Mallesons (KWM) advised Shanghai Pharmaceuticals Holding Co., Ltd (“Shanghai Pharma”) and Primavera Capital Fund II L.P. (“Primavera”) on their successful joint acquisition of 100% of ASX-listed Vitaco Holdings Ltd (“Vitaco”) by way of scheme of arrangement. Shanghai Pharma and Primavera paid Vitaco shareholders A$2.25 per share (less a dividend paid), valuing Vitaco at A$311.6 million. The scheme was implemented on 16 December 2016.

上海医药集团股份有限公司（简称“上海医药”）以及Primavera Capital Fund II L.P.（简称“春华”）在金杜律师事务所专业团队的协助下，通过协议完成对澳大利亚证券交易所上市公司Vitaco Holdings Ltd（简称“Vitaco”）100%股份的收购。上海医药和春华以每股2.25澳元（减支付的股利）收购Vitaco，对目标公司的总估值为3.116亿澳元。本次交易于2016年12月16日成功完成交割。
Continue Reading 金杜代表上海医药及Primavera完成收购澳洲上市公司Vitaco

作者：金杜律师事务所 King & Wood Mallesons

上海医药集团股份有限公司（简称“上海医药”）以及Primavera Capital Fund II L.P.（简称“春华”）在金杜律师事务所专业团队的协助下，通过协议收购澳大利亚证券交易所上市公司Vitaco Holdings Ltd（简称“Vitaco”）的100%股份。上海医药和春华将以每股2.25澳元收购Vitaco，交易对目标公司的估值为3.137亿澳元。

King & Wood Mallesons (KWM) is acting for Shanghai Pharmaceuticals Holding Co., Ltd (“Shanghai Pharma”) and Primavera Capital Fund II L.P. (“Primavera”) on their joint acquisition of 100% of ASX-listed Vitaco Holdings Ltd (“Vitaco”) by way of scheme of arrangement. Shanghai Pharma and Primavera are offering Vitaco shareholders A$2.25 per share (less any dividend paid), valuing Vitaco at A$313.7 million.
Continue Reading 金杜代表上海医药及Primavera收购澳洲上市公司Vitaco / King & Wood Mallesons acts for Shanghai Pharma and Primavera on acquisition of Vitaco